Loading patent…
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsRichard M Siegel, Francoise Meylan, Yun-Jeong Song
Estimating the term…
Provided are methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between DR3 and TL1A. The interaction between DR3 and TL1A can be blocked by reducing expression of TL1A. The interaction between DR3 and TL1A can be blocked by administration of anti-DR3 antibodies. The interaction between DR3 and TL1A can be blocked by administration of anti-TL1A antibodies. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a T cell component. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease (IBD).
A monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A.
A monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A, wherein the monoclonal antibody is humanized.
A monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A, wherein the monoclonal antibody is humanized, wherein the antibody comprises a humanized heavy chain variable region and a humanized light chain variable region.
A monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that:
A monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6.
A composition comprising a monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A, for the treatment of inflammatory or autoimmune disease.
A composition comprising a monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A, for the detection of cell surface expression of TL1A.
A composition comprising a monoclonal antibody produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, that binds specifically to TL1A and blocks the interaction between DR3 and TL1A, for the detection of soluble TL1A.
A method of treating an inflammatory or autoimmune disease in a subject, comprising administering to the subject an effective amount of anti-TL1A antibodies produced by a murine hybridoma clone selected from the group consisting of the anti-human TL1A clone 1A9 and the anti-human TL1A clone 1C6, which antibodies bind specifically to TL1A and block the interaction between DR3 and TL1A.
Dependencies are inferred from the claim text.